Roth Capital Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $58
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Roth Capital analyst Adam Walsh initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $58.
Roth Capital analyst Adam Walsh initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Buy rating and announces Price Target of $58.